The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Biosimilar Interleukins Market From 2026 To 2030?
The market size for biosimilar interleukins has witnessed substantial exponential growth in recent years. It is projected to expand from $7.52 billion in 2025 to $10.54 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 40.2%. The historical expansion of this market can be attributed to various factors, such as the elevated cost of originator interleukin biologics, the rising prevalence of autoimmune and inflammatory diseases, the increasing impact of rheumatoid arthritis and psoriasis, restricted patient access to biologic therapies, and an enhanced awareness of biologics in immune modulation.
The biosimilar interleukins market size is projected to experience substantial growth in the upcoming years, with an anticipated rise to $41.22 billion by 2030, driven by a compound annual growth rate (CAGR) of 40.6%. This expansion during the forecast period is primarily attributed to factors such as the expiry of patents for branded interleukins, the increasing number of biosimilar candidates in clinical development, greater physician acceptance of biosimilars, supportive government policies promoting biosimilar utilization, and the rising demand for affordable biologic treatments for cancer and immunological conditions. Key trends expected in the forecast period include the increasing adoption of biosimilar interleukins in the treatment of autoimmune diseases, a growing demand for cost-effective alternatives to originator biologics, the broadening of biosimilar approvals across multiple indications, expanded application of interleukins in managing chronic inflammatory disorders, and the reinforcement of regulatory frameworks that foster biosimilar uptake.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp
What Factors Are Contributing To The Growth Of The Biosimilar Interleukins Market?
The rising occurrence of autoimmune conditions like psoriasis and rheumatoid arthritis is projected to fuel the expansion of the interleukin biosimilars market over the prediction period. These disorders occur when the body’s immune cells fail to differentiate between healthy cells and harmful antibodies. Biologic medicines, including anti-interleukin antibodies, have demonstrated considerable clinical advantages in regulating, proliferating, activating, and migrating these cells. As an illustration, reports from February 2024 by the National Institutes of Health (NIH), a US-based biomedical research agency, indicate global annual increases in the incidence and prevalence of autoimmune diseases are estimated at 19.1% and 12.5% respectively. Consequently, the growing prevalence of autoimmune diseases is boosting demand for the biosimilar interleukins market and is anticipated to propel market growth.
How Is The Biosimilar Interleukins Market Organized By Segment Classification?
The biosimilar interleukins market covered in this report is segmented –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes
Subsegments:
1) By IL-17: Autoimmune Disease Treatment, Inflammatory Disease Management
2) By IL-23: Psoriasis Treatment, Inflammatory Bowel Disease (IBD) Treatment
3) By IL-1: Rheumatoid Arthritis Management, Other Autoimmune Disorders
4) By IL-5: Asthma Treatment, Eosinophilic Disorders
5) By IL-6: Rheumatoid Arthritis Management, Inflammatory Disease Treatment
What Trends Are Influencing The Biosimilar Interleukins Market?
Companies operating within the biosimilar interleukins market are innovating new products, such as Tofidence (tocilizumab-bavi), to boost their profitability. Tofidence, a monoclonal antibody, works by targeting and attaching to interleukin-6 receptors, and is employed in managing various inflammatory autoimmune disorders. For instance, in September 2023, Biogen Inc., a US-based biotechnology company, obtained FDA approval for Tofidence (tocilizumab-bavi) as the first biosimilar referencing Genentech’s Actemra (tocilizumab). Tofidence is administered through intravenous infusion and has gained approval for the treatment of severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
Who Are The Industry Participants Involved In The Biosimilar Interleukins Market?
Major companies operating in the biosimilar interleukins market are Mabpharm Limitied, Gedeon Richter plc, Bio-Thera Solutions Ltd., Sunshine Guojian Pharmaceutical, Stada Arzneimittel AG, Teva Pharmaceutical Industries, 3SBio Inc., Shanghai Fosun Pharmaceuticals, Novartis AG, Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche AG, Sanofi SA, Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Qilu Pharmaceutical, Tonghua Dongbao, PROBIOMED S.A. de C.V., Biosidus S.A., LG Life Sciences, Viatris Inc.
Get The Full Biosimilar Interleukins Market Report:
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report
Which Region Leads The Biosimilar Interleukins Market In Overall Market Size?
North America was the largest region in the biosimilar interleukins market in 2025. The regions covered in the biosimilar interleukins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Biosimilar Interleukins Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukin-global-market-report
Browse Through More Reports Similar to the Global Biosimilar Interleukins Market 2026, By The Business Research Company
Generic Pharmaceuticals Market Report 2026
https://www.thebusinessresearchcompany.com/report/generic-pharmaceuticals-global-market-report
Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report
Oncology Biosimilar Market Report 2026
https://www.thebusinessresearchcompany.com/report/oncology-biosimilar-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model